A study supported the ellipsoid zone loss as a meaningful biomarker that can be used to guide clinical trial design in ...

Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to ...

Faster thinning of cpRNFL and mGCIPL is associated with visual field progression in glaucoma, with rates of –1.02 and –1.04 ...

Thorne, MD, PhD, discusses evidence from the ADJUST trial, including relapse risk, retreatment success, and how clinicians ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf," cell therapies for serious medical conditions, ...